<?xml version="1.0" encoding="UTF-8"?>
<compound>
  <id type="integer">4485</id>
  <title>T3D4431</title>
  <common-name>Deoxyuridine</common-name>
  <description>2'-Deoxyuridine is a naturally occurring nucleoside. It is similar in chemical structure to uridine, but without the 2'-hydroxyl group. It is considered to be an antimetabolite that is converted to deoxyuridine triphosphate during DNA synthesis. Laboratory suppression of deoxyuridine is used to diagnose megaloblastic anemia due to vitamin B12 and folate deficiencies.</description>
  <cas>951-78-0</cas>
  <pubchem-id>13712</pubchem-id>
  <chemical-formula>C9H12N2O5</chemical-formula>
  <weight nil="true"/>
  <appearance>White powder.</appearance>
  <melting-point>167°C</melting-point>
  <boiling-point></boiling-point>
  <density nil="true"/>
  <solubility></solubility>
  <specific-gravity nil="true"/>
  <flash-point nil="true"/>
  <vapour-pressure nil="true"/>
  <route-of-exposure nil="true"/>
  <target nil="true"/>
  <mechanism-of-toxicity nil="true"/>
  <metabolism nil="true"/>
  <toxicity nil="true"/>
  <lethaldose nil="true"/>
  <carcinogenicity>No indication of carcinogenicity to humans (not listed by IARC).</carcinogenicity>
  <use-source>This is an endogenously produced metabolite found in the human body. It is used in metabolic reactions, catabolic reactions or waste generation.</use-source>
  <min-risk-level nil="true"/>
  <health-effects nil="true"/>
  <symptoms nil="true"/>
  <treatment nil="true"/>
  <created-at type="dateTime">2014-08-29T06:51:15Z</created-at>
  <updated-at type="dateTime">2026-05-14T17:32:33Z</updated-at>
  <interacting-proteins nil="true"/>
  <wikipedia>Deoxyuridine</wikipedia>
  <uniprot-id nil="true"/>
  <kegg-compound-id>C00526</kegg-compound-id>
  <omim-id nil="true"/>
  <chebi-id>16450</chebi-id>
  <biocyc-id>DEOXYURIDINE</biocyc-id>
  <ctd-id nil="true"/>
  <stitch-id nil="true"/>
  <drugbank-id>DB02256</drugbank-id>
  <pdb-id>DUR</pdb-id>
  <actor-id nil="true"/>
  <organism nil="true"/>
  <export type="boolean">true</export>
  <metabolizing-proteins nil="true"/>
  <transporting-proteins nil="true"/>
  <moldb-smiles>OC[C@H]1O[C@H](C[C@@H]1O)N1C=CC(=O)NC1=O</moldb-smiles>
  <moldb-formula>C9H12N2O5</moldb-formula>
  <moldb-inchi>InChI=1S/C9H12N2O5/c12-4-6-5(13)3-8(16-6)11-2-1-7(14)10-9(11)15/h1-2,5-6,8,12-13H,3-4H2,(H,10,14,15)/t5-,6+,8+/m0/s1</moldb-inchi>
  <moldb-inchikey>MXHRCPNRJAMMIM-SHYZEUOFSA-N</moldb-inchikey>
  <moldb-average-mass type="decimal">228.202</moldb-average-mass>
  <moldb-mono-mass type="decimal">228.074621504</moldb-mono-mass>
  <origin>Endogenous</origin>
  <state>Solid</state>
  <logp>-1.51</logp>
  <hmdb-id>HMDB00012</hmdb-id>
  <chembl-id>CHEMBL353955</chembl-id>
  <chemspider-id>13118</chemspider-id>
  <structure-image-file-name nil="true"/>
  <structure-image-content-type nil="true"/>
  <structure-image-file-size type="integer" nil="true"/>
  <structure-image-updated-at type="dateTime" nil="true"/>
  <biodb-id nil="true"/>
  <synthesis-reference>&lt;p&gt;Kenzo Watanabe, Yoshinori Kato, Masahiko Saito, Takeo Oba, Hisashi Fukushima, Takeshi Hara, &amp;#8220;5-fluoro-2&amp;#8217;-deoxyuridine derivatives and a process for the preparation thereof.&amp;#8221; U.S. Patent US4605645, issued May, 1984.&lt;/p&gt;</synthesis-reference>
  <structure-image-caption nil="true"/>
  <chemdb-id>CHEM003391</chemdb-id>
  <dsstox-id>DTXSID30883621</dsstox-id>
  <toxcast-id nil="true"/>
  <stoff-ident-origin nil="true"/>
  <stoff-ident-id nil="true"/>
  <susdat-id nil="true"/>
  <iupac>1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,3,4-tetrahydropyrimidine-2,4-dione</iupac>
  <moldb-polar-surface-area>99.1</moldb-polar-surface-area>
  <moldb-refractivity>51.05490000000001</moldb-refractivity>
  <moldb-polarizability>21.061427774885466</moldb-polarizability>
  <moldb-rotatable-bond-count>2</moldb-rotatable-bond-count>
  <moldb-acceptor-count>5</moldb-acceptor-count>
  <moldb-donor-count>3</moldb-donor-count>
  <moldb-pka-strongest-acidic>9.705729612726527</moldb-pka-strongest-acidic>
  <moldb-pka-strongest-basic>-2.9780835884997945</moldb-pka-strongest-basic>
  <moldb-physiological-charge>0</moldb-physiological-charge>
  <moldb-number-of-rings>2</moldb-number-of-rings>
  <moldb-alogps-logp>-1.49</moldb-alogps-logp>
  <moldb-alogps-logs>-0.40</moldb-alogps-logs>
  <moldb-alogps-solubility>9.06e+01 g/l</moldb-alogps-solubility>
</compound>
